+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma

Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma

Leukemia and Lymphoma 56(7): 2019-2024

Twelve consecutive patients with classical Hodgkin lymphoma (HL) involving diaphragmatic or subdiaphragmatic regions were treated on an institutional review board-approved outcomes tracking protocol. All patients underwent treatment with proton therapy following chemotherapy and had comparative three-dimensional conformal photon radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) plans to evaluate differences in dose to organs at risk (OARs). Among the cohort, stomach doses with 3DCRT, IMRT and proton therapy were 21 Gy (median), 14 Gy and 6 Gy, respectively. Median dose reductions with proton therapy compared with 3DCRT and IMRT were 13 Gy (p = 0.0022) and 8 Gy (p = 0.0022) for the stomach. Additionally, there was significant dose reduction using proton therapy for the liver, pancreas, bowel, left kidney and right kidney. Proton therapy reduces the dose to the stomach, liver, pancreas, small bowel and kidneys compared with 3DCRT or IMRT in patients with HL requiring abdominal radiotherapy. These dose reductions are expected to translate into lower risks of secondary cancers and other late toxicities in survivors of HL.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055260543

Download citation: RISBibTeXText

PMID: 25315071

DOI: 10.3109/10428194.2014.975802

Related references

Proton therapy in the management of non-Hodgkin lymphoma. Leukemia and Lymphoma 56(9): 2608-2612, 2016

Proton beam therapy for the management of mediastinal Hodgkin lymphoma in a young female patient. Cancer Radiotherapie 22(3): 296-298, 2018

Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Annals of Oncology 28(9): 2179-2184, 2018

The Impact of IMRT and Proton Beam Therapy on Overall Survival for Patients With Hodgkin Lymphoma. International Journal of Radiation Oncology*biology*physics 93(3): S80-S81, 2015

Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential. Journal of Applied Clinical Medical Physics 16(5): 167–178, 2016

Phase 2 Study of Consolidative Involved-Node Proton Therapy in Patients With Hodgkin Lymphoma: Early Outcomes. International Journal of Radiation Oncology*biology*physics 87(2): S162-S163, 2013

Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany?. Annals of Oncology 21(10): 2045-2051, 2011

Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. Acta Oncologica 55(11): 1378-1380, 2016

(P124) dosimetric comparison of three-dimensional conformal proton radiotherapy and intensity-modulated proton therapy for treatment of pediatric hodgkin lymphoma. Oncology 29(4 Suppl 1): -, 2015

Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy. Cancer Radiotherapie 20(2): 98-103, 2016

Proton therapy for Hodgkin lymphoma. Current Hematologic Malignancy Reports 9(3): 203-211, 2015

Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy. Immunotargets and Therapy 4: 55-63, 2015

Predictive value of lymphography for sites of subdiaphragmatic disease encountered at staging laparotomy in newly diagnosed Hodgkin's disease and non-Hodgkin's lymphoma. Journal of Clinical Oncology 1(9): 532-536, 1983

Proton Therapy for Pediatric Hodgkin Lymphoma. Pediatric Blood and Cancer 63(9): 1522-1526, 2017

Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma. Leukemia and Lymphoma 51(8): 1559-1562, 2010